Long-term safety study of an antibody treatment for heart condition
Part of Heart & circulation clinical trials.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the full treatment period (including the final check-up visit) of the earlier Study 301 trial.
- You must not have stopped taking the study drug early or withdrawn from Study 301.
- You must not have any known or suspected allergy to proteins or any part of the study drug.
- You must not have had a heart transplant or a permanent mechanical heart assist device.
- You must not be currently participating in another investigational study or have taken an investigational drug within the last 30 days or five half-lives (whichever is longer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This study follows people who completed an earlier trial of the drug acoramidis for a heart condition called ATTR-CM. It aims to check the long-term safety and how well people tolerate the drug.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
Hear when a new Transthyretin Amyloid Cardiomyopathy (ATTR-CM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.